000			01413nam a2200277 4500
001			ESSALUD
005			20260821102447.0
007			ta
008			t pe ||||| |||| 00| 0 spa d
040			_aBMG
041			_aeng
100			_aHaffajee, Rebecca L. _eAutor _954222
245			_aMarijuana Rescheduling — A Game Changer for Research?
300			_apáginas: 729-731
520			_aOn April 22, 2026, the U.S. acting attorney general issued a final rule immediately reclassifying state-licensed medical marijuana products and future Food and Drug Administration (FDA)–approved marijuana products under Schedule III of the Controlled Substances Act. Medical marijuana (cannabis containing ≥0.3% tetrahydrocannabinol), now legal in 40 states, three territories, and the District of Columbia, was previously federally designated as a Schedule I drug — the category of drugs that are the most tightly controlled.
650			_a MEDICAMENTOS, DISPOSITIVOS Y LA FDA _954223
650			_aHEMATOLOGÍA _97422
650			_aONCOLOGÍA GENERAL _954224
650			_aDOLOR
650			_aTRATAMIENTOS EN ONCOLOGÍA _953734
650			_aDERECHO SANITARIO _948689
700			_aMikos, Robert A. _954225
700			_aCooper, Ziva D. _954226
773	0		_022717 _922650 _dMassachusetts NEJM Group _oNEJM12 _tThe New England Journal of Medicine _wESSALUD _x0028-4793
942			_cARTICULOS _e2026-08-21 _zsqb
999			_c22848 _d22848